Taysha Gene Therapies (TSHA) Current Assets (2019 - 2026)
Taysha Gene Therapies (TSHA) posted Current Assets of $282.2 million for Q1 2026, down 13.06% sequentially from $324.6 million in Q4 2025, and up 133.83% YoY from $120.7 million in Q1 2025.
Taysha Gene Therapies (TSHA) Current Assets (2019 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Current Assets for 8 years, with the latest figure at $282.2 million in Q1 2026.
- Quarterly Current Assets rose 133.83% year-over-year to $282.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $282.2 million (up 133.83% YoY) and the FY2025 annual result came in at $324.6 million, up 128.42% from the prior year.
- Current Assets eased to $282.2 million in Q1 2026 per TSHA's latest filing, from $324.6 million in the prior quarter.
- Over five years, Current Assets peaked at $324.6 million in Q4 2025 and troughed at $43.0 million in Q3 2022.
- A 5-year average of $160.5 million and a median of $142.1 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets sank 78.19% in 2022, then soared 299.53% in 2023.
- Over 5 years, Current Assets stood at $96.4 million in 2022, then jumped by 55.44% to $149.9 million in 2023, then retreated by 5.16% to $142.1 million in 2024, then jumped by 128.42% to $324.6 million in 2025, then retreated by 13.06% to $282.2 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $282.2 million, $324.6 million, and $300.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 461.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 461.43 Mn |
| Mar 31, 2026 | 282.25 Mn |
| Dec 31, 2025 | 324.65 Mn |
| Sep 30, 2025 | 299.95 Mn |
| Jun 30, 2025 | 316.26 Mn |
| Mar 31, 2025 | 120.71 Mn |
| Dec 31, 2024 | 142.13 Mn |
| Sep 30, 2024 | 161.56 Mn |
| Jun 30, 2024 | 178.47 Mn |
| Mar 31, 2024 | 130.60 Mn |
| Dec 31, 2023 | 149.87 Mn |
| Sep 30, 2023 | 171.81 Mn |
| Jun 30, 2023 | 54.12 Mn |
| Mar 31, 2023 | 72.36 Mn |
| Dec 31, 2022 | 96.42 Mn |
| Sep 30, 2022 | 43.00 Mn |
| Jun 30, 2022 | 76.84 Mn |
| Mar 31, 2022 | 106.89 Mn |
| Dec 31, 2021 | 159.60 Mn |
| Sep 30, 2021 | 197.17 Mn |